| Michele L Mack, CRNA | |
|
18100 Oakwood Blvd, Suite 100, Dearborn, MI 48124-4085 | |
| (313) 253-2000 | |
| Not Available |
| Full Name | Michele L Mack |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 30 Years |
| Location | 18100 Oakwood Blvd, Dearborn, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013941921 | NPI | - | NPPES |
| 4852368 | Medicaid | MI | |
| 4793024 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 4704172231 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harper University Hospital | Detroit, MI | Hospital |
| Karmanos Cancer Center | Detroit, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Superior Anesthetists Associates Inc | 5890784987 | 61 |
| Northstar Anesthesia Of Michigan Pllc | 9638481591 | 182 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Anesthesia Services Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437268992 PECOS PAC ID: 0042124885 Enrollment ID: O20031117000499 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Ascension Providence Rochester Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235252321 PECOS PAC ID: 8820994098 Enrollment ID: O20031209000552 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Northstar Anesthesia Of Michigan Ii Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437268026 PECOS PAC ID: 7911895164 Enrollment ID: O20040309000625 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Superior Anesthetists Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831144518 PECOS PAC ID: 5890784987 Enrollment ID: O20040512000785 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Surgical Centers Of Michigan Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1962463133 PECOS PAC ID: 1355393364 Enrollment ID: O20050218000062 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Ambulatory Anesthesia Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952350555 PECOS PAC ID: 5092729020 Enrollment ID: O20060130000526 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Southfield Rehabilitation Company |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790785095 PECOS PAC ID: 6709872617 Enrollment ID: O20060414000038 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Macomb Endoscopy Center Plc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1780923128 PECOS PAC ID: 1850536012 Enrollment ID: O20130319000064 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Entity Name | Northstar Anesthesia Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871986372 PECOS PAC ID: 9638481591 Enrollment ID: O20150707000070 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michele L Mack, CRNA 18100 Oakwood Blvd, Suite 100, Dearborn, MI 48124-4085 Ph: (313) 253-2000 | Michele L Mack, CRNA 18100 Oakwood Blvd, Suite 100, Dearborn, MI 48124-4085 Ph: (313) 253-2000 |
News Archive
ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.
Researchers using a rodent model of childhood manganese exposure have found that too much manganese early in development causes lasting attention deficits and other impairments.
Cleveland Clinic Children's Hospital has launched a study to determine whether genetic markers can be used to help identify children who are at risk of developing autism.
People with epilepsy want their health care providers to tell them about a rare risk of death associated with the disorder, according to a preliminary study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.
An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.
› Verified 6 days ago
Megan Nicole Sanborn, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-436-2374 | |
Michael Kroll, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 18101 Oakwood Blvd, Anesthesia Dept, Dearborn, MI 48124 Phone: 313-593-7820 Fax: 313-593-8894 | |
Melody Y Lowe, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 18100 Oakwood Blvd, Suite 100, Dearborn, MI 48124 Phone: 313-253-2000 Fax: 313-253-2028 | |
Robert F Mrowka, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 18101 Oakwood Blvd, Anesthesia Dept, Dearborn, MI 48124 Phone: 313-593-7820 Fax: 313-593-8894 | |
Calvin Stewart, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 18100 Oakwood Blvd, Suite 100, Dearborn, MI 48124 Phone: 313-253-2000 | |
David C Whitesell, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 18100 Oakwood Blvd, Suite 100, Dearborn, MI 48124 Phone: 313-253-2000 |